

**Paulina Deming, PharmD, PhC**  
**Associate Professor of Pharmacy**

The University of New Mexico Health Sciences Center (UNMHSC)  
College of Pharmacy  
MSC09 5360  
1 University of New Mexico  
Albuquerque, NM 87131-0001  
Phone: 505.272.0194  
Fax: 505.272.6749  
Email: [pdeming@salud.unm.edu](mailto:pdeming@salud.unm.edu)

**EDUCATION**

---

Infectious Disease Pharmacotherapy Resident	University Hospital Albuquerque, NM	July 2005- June 2006
Pharmacy Practice Resident	University Hospital Albuquerque, NM	July 2004- June 2005
Doctor of Pharmacy	University of New Mexico College of Pharmacy Albuquerque, NM	Aug 2001- May 2004
Bachelor of Science Biology	University of New Mexico Albuquerque, NM	Aug 1993-Dec 1997

**PROFESSIONAL EXPERIENCE**

---

Associate Professor of Pharmacy Internal Medicine	UNM College of Pharmacy	July 2013- Present
Assistant Professor of Pharmacy Internal Medicine	UNM College of Pharmacy	Feb 2007- June 2013
Assistant Director	Project ECHO Hepatitis Programs and UNMH Hepatitis C Clinic	Sept 2012- Present
Clinical Pharmacist	Project ECHO and UNMH Hepatitis C Clinic	Feb 2007- Present
Adjunct Professor	UNM College of Pharmacy	July 2006-Feb 2007
Chief Resident	UNMHSC Residency Program	July 2005-July 2006
Kinetics Monitoring	UNMH In-Patient Pharmacy Albuquerque, NM	July 2005-July 2006

In-Patient Pharmacy Staff	UNMH In-Patient Pharmacy Albuquerque, NM	July 2004-July 2005
Pharmacy Intern	Lovelace Montgomery Pharmacy Albuquerque, NM	2002- 2004
Conference Staff	Center for Strategic Decision Research Menlo Park, CA	June-July 2000 May-June 2001
Project Manager	ePAC Advanced Printing and Logistics San Leandro, CA	Aug 1999- May 2001
Consultant	ePAC Advanced Printing and Logistics San Leandro, CA	Mar 1999- Aug 1999

## CLINICAL EXPERIENCE

Truman Medical Group HIV-Hepatitis C (HCV) Coinfection Clinic Dr. Karla Thornton, MD Duties:	UNMHSC	Aug 2013- Present
<ul style="list-style-type: none"> <li>• Evaluate patients for initiation of HCV therapy including initial screening and diagnosis with relevant history, physical exam, and laboratory assessment</li> <li>• Evaluate patients on therapy for complications of therapy including side effects and related medical issues</li> <li>• Follow up care on patients including those on therapy and those who have completed therapy or patients who are not candidates for treatment</li> </ul>		

ECHO Institute Medical Directors: Dr. Sanjeev Arora, MD, Dr. Karla Thornton MD Community Hepatitis C Clinic		Feb 2007- Present
<ul style="list-style-type: none"> <li>• Serve as expert faculty for clinic; co-facilitate</li> <li>• Assist rural healthcare providers in providing HCV treatment including evaluation of eligibility of treatment, optimization of pharmacological therapy for hepatitis, liver disease, HCV resistance profiles, and underlying comorbidities</li> <li>• Prepare and maintain clinic protocol, treatment algorithms, monitoring flowsheets</li> <li>• Provide monthly training for new HCV providers</li> <li>• Implement weekly didactic curriculum</li> <li>• Provide educational presentations for clinic participants</li> <li>• Liaison with practitioners interested in implementing ECHO including Indian Health Services and collaborating partners at University of Washington, University of Utah, St. Lukes (Houston) and St. Joseph's Hospital (Phoenix) through the ECHO HCV Consortium</li> </ul>		

Department of Corrections HCV Clinic		Feb 2011- Dec 2012, Aug 2015- Present
<ul style="list-style-type: none"> <li>• Medical director of clinic since 2019</li> <li>• Facilitate teleECHO clinics</li> <li>• Serve as expert faculty for clinic</li> </ul>		

- Assist clinicians in the corrections systems in providing HCV treatment for selected inmates including evaluation of liver disease, selecting optimal HCV therapies, management and follow-up of patients on therapy, management and follow up of patients with cirrhosis
- Prepare and maintain clinic protocol, treatment algorithms, monitoring flowsheets, and patient and provider handouts
- Provide HCV training for new HCV providers
- Implement weekly didactic curriculum
- Provide educational presentations for clinic participants

Indian Country HCV TeleECHO Clinic (formerly: Indian Health Services HCV ECHO) 2014- present

- Medical director of clinic since 2019
- Serve as expert faculty for clinic; co-facilitate
- Assist rural healthcare providers in providing HCV treatment including evaluation of eligibility of treatment, optimization of pharmacological therapy for hepatitis, liver disease, HCV resistance profiles, and underlying comorbidities
- Prepare and maintain clinic protocol, treatment algorithms, monitoring flowsheets
- Provide monthly training for new HCV providers
- Implement bi-weekly didactic curriculum
- Provide educational presentations for clinic participants

HCV Elimination for Country of Georgia 2016- Present

- Serve as expert faculty for clinic
- Assist healthcare providers in the Country of Georgia in implementing the ECHO model
- Assist healthcare providers in the Country of Georgia in optimizing HCV treatment in difficult to treat patient populations
- Prepare and maintain clinic protocol, treatment algorithms, monitoring flowsheets
- Co-direct curriculum schedule and plan
- Provide educational presentations for clinic participants

HBV ECHO: Reducing Perinatal Transmission (HRSA funded) 2016- 2018

- Prepare and maintain clinic presentation forms
- Develop curriculum
- Develop learning points for each clinical session for on-line learning community

Great Plains Indian Country HCV ECHO 2018-present

- Medical director and faculty expert for first pharmacy-lead HCV ECHO
- Provide HCV treatment recommendations to clinicians working in Indian Health Systems, Tribal and Urban Indian Health
- Provide curricular presentations

---

Gastroenterology/ HCV Clinic (UNMH) Feb 2007- Present  
 Dr. Sanjeev Arora, MD Feb 2005-June 2006

Duties:

- Evaluate patients for initiation of hepatitis therapy including initial screening and diagnosis with relevant history, physical exam, and laboratory assessment
- Evaluate patients on therapy for complications of therapy including side effects and related medical issues
- Follow up care on patients including those on therapy and those who have completed therapy or patients who are not candidates for treatment

- Provide mentorship in patient care and physical assessment in ambulatory care setting for pharmacy resident
- Review clinic protocols and procedures
- Serve as point of contact for nursing concerns regarding patient treatment

## MENTORSHIP

---

### Residency Mentor

Chelsea Rodriguez, PharmD	2019-
Jessica Lewis, PharmD	2018-2019
M. Gabriela Cabanilla, PharmD	2017-2018
Laura Garcia, PharmD	2016-2017
Andrea Brandt, PharmD	2015-2016
Megan Fletcher, PharmD	2014-2015
Brandon Dionne, PharmD	2013-2014
Joseph Llewellyn, PharmD	2012-2013
Melinda Montoya, PharmD	2011-2012
Matthew London, PharmD	2010-2011
Michael North, PharmD	2009-2010
Chris Werth, PharmD	2008-2009
Kent Montierth, PharmD	2007-2008

College of Pharmacy Cares (faculty student mentor)	Jan. 2018-present
Research Mentor: Brenna Darling (PharmD candidate)	Aug. 2017-2020
E-Portfolio Mentor (faculty student mentor)	Dec 2009-2011

## TEACHING RESPONSIBILITIES

---

### Preceptor: ECHO Interprofessional Clinical Clerkship (co-preceptor with Dr. Joe Anderson and IPE team):

- 3 students (2 pharmacy, 1 medical student) Feb. 2020
- 4 students (2 pharmacy, 2 medical students) Jan. 2020
- 4 students (2 pharmacy, 2 medical students) Feb. 2019
- 3 students (2 pharmacy students, 1 medical student) Jan. 2019
- 3 students (2 pharmacy students, 1 medical student) Feb. 2018
- 3 students (2 pharmacy students, 1 medical student) Jan. 2018
- 4 students (2 pharmacy students, 2 medical students) Feb. 2017
- 2 pharmacy students Jan. 2017
- 6 students (2 pharmacy students, 2 medical students, 2 nursing students) Feb. 2016
- 8 students (2 pharmacy students, 4 medical students, 2 nursing students) Jan. 2016
- 6 students (2 pharmacy students, 2 medical students, 2 nursing students) Feb. 2015
- 5 students (1 pharmacy resident, 2 pharmacy students, 1 nurse practitioner, 1 nursing student) Jan. 2015
- 8 students (6 pharmacy students and 2 medical students) March 2014-August 2014

### Preceptor: Project ECHO Advanced Liver Care Rotation

- 6 pharmacy students June 2019-Dec 2019
- 4 pharmacy students June 2018-May 2019
- 6 pharmacy students and 1 infectious disease pharmacotherapy resident June 2017-Jan 2018
- 6 pharmacy students and 1 infectious diseases pharmacotherapy resident between June 2016-May 2017
- 5 pharmacy students and 1 pharmacy resident between June 2015- May 2016
- 4 pharmacy students between June 2014- May 2015

### Preceptor: Internal Medicine Clinical Clerkship

- 4 students and 4 residents between July 2013- June 2014
- 16 students and 4 residents between June 2012- July 2013
- 16 students and 4 residents between June 2011-May 2012
- 17 students and 4 residents between June 2010-May 2011
- 16 students and 4 residents between June 2009-May 2010
- 16 students and 4 residents between June 2008-May 2009

31 students and 4 residents between July 2007-May 2008

Co-Instructor of Record: Integrated Pharmacotherapy 845	2018, 2019
Instructor of Record: Integrated Pharmacotherapy 840	2018, 2019
Lecturer: Integrated Pharmacotherapy 810: Dose adjustments in hepatic disease (2 hrs)	2018, 2019
Lecturer: Integrated Pharmacotherapy 810: Thyroid disease (1 hour)	2018, 2019
Lecturer: Integrated Pharmacotherapy 830: Pancreatitis, GERD/PUD, cirrhosis management, drug induced liver injury (8 hours)	2019
Lecturer: Integrated Pharmacotherapy 835: Pancreatitis, GERD/PUD, cirrhosis management, drug induced liver injury (8 hours)	2018
Lecturer: Pharmacotherapy 751: Hepatitis A and B (1 hour)	2015, 2016, 2017
Lecturer: Pharmacotherapy 751: Hepatitis C (4 hours)	2015, 2016, 2017
Lecturer: Pharmaceutical Care Lab- Chronic Liver Disease Lab (2 hours)	2015-present
Instructor of Record: Pharmacotherapy 752 6 credit hour course with multiple block instructors	2012-13, 2016-18
Lecturer: Pharmaceutical Lab – Chronic Liver Disease Assessment (3 hours)	2015, 2016
Guest Lecturer: UNM Physician Assistant Course PAST 533: Viral hepatitis	2013, 2017, 2018
Lecturer: Pharmacotherapy 751: Hepatitis C (2 hours)	Oct 2012- 2014
Lecturer: Pharmacotherapy 751: Hepatitis B (2 hours)	Oct 2012- 2014
Lecturer: Pharmacotherapy 751: Hepatitis A (1 hour)	Oct 2012-2014
Block Coordinator: Gastroenterology in Pharmacotherapy 751 Provided 8 lectures approx. 2 hours each and coordinated with guest lecturers	2010-2016
Lecturer: Pharmacotherapy 752: Anemia II/Drug-Induced Hematology Disorders (2 hours)	2012
Lecturer: Pharmacotherapy 752: Introduction to Hematology/Anemia I (2 hours)	2012- 2014
Lecturer: Pharmacotherapy 752: Epilepsy (2 hours)	2012
Block Coordinator: Neurology in Pharmacotherapy 752	2012
Block Coordinator: Immunology/ Hematology in Pharmacotherapy 752	2012
Lecturer: Pharmaceutical Care Lab- Chronic Liver Disease Lab 3 days x 1.5 hours	2010
Faculty Facilitator: Pharmacy 765L: Pharmaceutical Care Lab	2010
Lecturer Pathophysiology: GERD, PUD, IBS, IBD (2 hrs)	2010-2016
Lecturer Pathophysiology: Liver Disease (2 hrs)	2010-2016

Lecturer Pharmacotherapy 739: Thyroid Disorders (1 hr)	2010-2016
Lecturer: Pharmacy 784 Infectious Diseases Elective: HCV (2 hrs)	2016, 2017
Lecturer: Pharmacy 784 Infectious Diseases Elective: HIV-HCV Coinfection (2 hrs)	2013-2015
Lecturer: Pharmacy 784 Infectious Diseases Elective: HIV-HCV Coinfection (1 hr)	2010-2012
Lecturer: Pharmacy 726: Dose Adjustments in Hepatic Disease (2 hrs)	2009, 2011-14, 2016-17
Block Coordinator: Critical Care and Nutrition in Pharmacotherapy 751	2009, 2014
Lecturer: Pharmacotherapy 719 (Self-Care): Diarrhea and Constipation (2 hrs)	2009
Lecturer: Pharmacotherapy 719 (Self-Care): GERD and Nausea and Vomiting (2 hrs)	2009
Lecturer: Pharmacotherapy 751: Community-Acquired Pneumonia (2 hrs)	2009
Block Coordinator: Gastroenterology in Pharmacotherapy 751 Provided 8 lectures approximately 2 hours each and coordinated with guest lecturers	2009
Lecturer: Pharmaceutical Care Lab- Chronic Liver Disease Lab (1.5 hrs)	2009
Lecturer: Hepatic Dysfunction as a Risk Factor for Infectious Disease Infectious Disease Elective	2009
Lecturer Pharmacokinetics 726: Dose Adjustments in Hepatic Disease and Case Session (2 hrs)	2008
Lecturer: Pharmaceutical Care Lab- Chronic Liver Disease Lab (1.5 hrs)	2008
Block Coordinator: Critical Care and Nutrition in Pharmacotherapy 751	2008
Block Coordinator: Gastroenterology in Pharmacotherapy 751 Provided 8 lectures approximately 2 hours each and coordinated with guest lecturers	2008
Block Coordinator: Internal Medicine in Pharmacotherapy 752 Provided 6 lectures approximately 2 hours each and coordinated with guest lecturers	2008
Lecturer Pharmacotherapy 739: Thyroid Disorders (2 hrs)	2008
Lecturer Pathophysiology: GERD, PUD, IBS, IBD (2 hrs)	2008
Lecturer Pathophysiology: Liver Disease (2 hrs)	2008
Physical Assessment and Critical Skills 750-Lab Section Instructor (3 hrs)	2007-08
Instructor of Record: Pharmacotherapy 751 6 credit hour course with multiple block instructors	2007-09, 2014
Lecturer Pharmacotherapy 751: Thyroid Disorders (2 hrs)	2007
Lecturer Pharmacy 719 Self-Care Therapeutics: GERD/ PUD/ Nausea and Vomiting (1.5 hrs)	2007
Lecturer Kinetics 745: Dose Adjustments in Hepatic Disease (1 hr)	2007

Lecturer Pharmacokinetics 726: Dose Adjustments in Hepatic Disease (1 hr)	2007
CE Lecture for the Infectious Disease Fellows and Attending Physicians: Opportunistic Infections	2006
OSCE Evaluator for Physical Assessment and Critical Skills	2006, 2012-14
Guest Lecturer for Pharmacotherapy 752: Upper Respiratory Tract Infections (2 hrs)	2006
Guest Lecturer for Pharmacotherapy 752: Sexually Transmitted Diseases (2 hrs)	2006
Student-Centered, Problem-Based Learning, 712/722 (6 hrs/week X 8 weeks)	2004-05
Preceptor Pharmacy 770	2004-06
Assistant for Patient Assessment Lab 750L (3 hours/week x 12 weeks)	2004
Guest Lecturer for Pharmacotherapy 751: Nausea and Vomiting (2 hours)	2004

### GRANTS SUBMITTED

---

**ABBVIE Investigator Initiated Research Program** \$200,000 Integration of HCV Treatment into Substance Use Disorder Clinics: Integrating the ECHO Model to Provide Concomitant HCV Treatment Utilizing Existing Resources (Submitted)  
Role: PI

**Centers for Disease Control: Community-Based Programs to Test and Cure Hepatitis C Grant** \$20,000,000 New Mexico comprehensive hepatitis intervention program. (Not funded)  
Role: Co-I

**University of New Mexico Resource Allocation Committee (RAC) Grant** \$10,000 Optimization of hepatitis B vaccine in HIV-infected patients. (Funded) Project Period 2010-2011  
Role: Co-I

**Society of Infectious Disease Pharmacists/ Astellas Research Award** \$20,000 Identification of MRSA strains as an independent risk factor in hospitalized patient outcome. (Funded) Project Period 2007-2010  
Role: PI

**Society of Infectious Disease Pharmacists/ Pfizer/ Wyeth Research Award** \$20,000 Identification of MRSA strains as an independent risk factor in hospitalized patient outcome. (Not funded) Project Period 2005-2006  
Role: PI

**American College of Clinical Pharmacy/Frontiers Career Development Research Award** \$30,000 MRSA strains as an independent risk factor in hospitalized patient outcome. (Not funded) Project Period 2007-2008  
Role: PI

### ABSTRACTS

---

Martin M, Ho Macy, Koren D, Mehta S, Mennen K, Hammond K, Naik S, Teply R, **Deming P**, Radley A. Pharmacist Driven Models of Care for Hepatitis C Virus Elimination: Real World Cohorts. *American College of Clinical Pharmacy (ACCP) Annual Meeting*. New York, NY. Oct 26-29, 2019.

Cabanilla MG, **Deming P**, Qualls C, Arora S, Thornton K. Hepatitis C virus sustained virologic response rates in Hispanics. *American Association for the Study of Liver Diseases 2018 Annual Meeting*; San Francisco, CA. November 2018.

**Deming P**, Moran B, Gazarian N, Owen J, Stephens D, Leston J. Great Plains pharmacy-driven HCV ECHO-Building capacity and filling clinical gaps to cure hepatitis C. *American College of Clinical Pharmacy (ACCP) Global Conference on Clinical Pharmacy*. Seattle, WA. Oct 20-23, 2018.

Jakeman B, Vu TA, **Deming P**, Pineda L, Tomaszewski L, Pérez S, **Thornton K**. Integrating pharmacists into the treatment management team for patients living with human immunodeficiency virus and hepatitis C virus. *American College of Clinical Pharmacy (ACCP) Global Conference on Clinical Pharmacy*. Seattle, WA. Oct 20-23, 2018.

Stephens D, Leston J, **Deming P**. Eliminating Hepatitis C in Indian Country Using the ECHO Model. National Indian Health Board 2018 National Tribal Health Conference. Oklahoma City, OK. September 2018.

Cabanilla MG, **Deming P**, Martinez L, Thornton K, Arora S. Hepatitis C virus sustained virologic response rates in Hispanics. *Annual American Society for Health-Systems Pharmacists*. Orlando, FL. December 2017.

Thornton K, Price JC, **Deming P**, Sedillo ML, Scott J, Aronsohn AI, Box TD, Sussman NL, Khaderi S, Gish RG, Page K, Arora S. Expanding HCV treatment access: training primary care providers in the US using the ECHO model. *American Association for the Study of Liver Diseases 2017 Annual Meeting*; Washington DC. October 2017.

David C, David D, Essex W, **Deming P**, Qualls CR, Mera J. Hepatitis C treatment outcomes in a pharmacist-managed clinic in a rural tribal health system. *American Association for the Study of Liver Diseases 2017 Annual Meeting*; Washington DC. October 2017.

Thornton K, **Deming P**, Sedillo ML, Wang G, Gish R, Pham T. HBV ECHO: Reducing Perinatal Transmission. Community Health Institute and Expo: San Diego, CA. August 2017.

Thornton K, **Deming P**, Sedillo M, Arora S. Treatment of chronic hepatitis virus (HCV) infections with direct acting antivirals in the New Mexico State prison system using the Project ECHO model. *52<sup>nd</sup> Annual Meeting of the European Association for the Study of the Liver*; Amsterdam, Netherlands. Abstract FRI-186. April 2017.

Thornton K, **Deming P**, Sedillo M, Qualls C, Box T, Scott J, Cox P, Mera J, Miller A, Manch R, Kohli A, Gish R, Moore A, Sussman N, Khaderi S, Arora S. Low sustained virologic response (SVR) rates in genotype (GT) 2 and 3 patients with quantifiable hepatitis C virus (HCV) at week 4 of treatment with sofosbuvir (SOF) containing regimens. *51<sup>st</sup> Annual Meeting of the European Association for the Study of the Liver*; Barcelona, Spain. Abstract 126049 SAT-193. April 2016.

Georgie F, Nafisi S, Kohli A, Thornton K, Reynolds J, Moore A, Gish R, Scott J, **Deming P**, Sedillo M, Qualls C, Box T, Cox P, Mera J, Miller A, Sussman N, Khaderi S, Manch R, Arora S. Primary care physicians utilizing the ECHO model equally effective as subspecialists treating HCV using DAA-only regimens. Results of the ECHO model. *51<sup>st</sup> Annual Meeting of the European Association for the Study of the Liver*; Barcelona, Spain. Abstract 126116 SAT-260. April 2016.

Brandt A, **Deming P**, Thornton K, Arora S. Impact of treatment delay on clinical outcomes in hepatitis C patients. *50<sup>th</sup> Annual American Society for Health-Systems Pharmacists* New Orleans, LA. December 2015.

Garcia R, Arora S, **Deming P**, Thornton K. Hepatitis C treatment experience in the New Mexico state prison system using the ECHO model. *2015 National Summit on HCV and HIV Diagnosis, Prevention, and Access to Care*. Arlington, VA. June 4-6, 2015.

Thornton K, **Deming P**, Manch R, et al. Response guided therapy is not dead: low sustained virologic response (SVR) rates in patients with detectable hepatitis C virus (HCV) at week 4 of treatment with sofosbuvir (SOF)-containing regimens. *50th Annual Meeting of the European Association for the Study of the Liver*; April 22-26, 2015; Vienna, Austria. Abstract LB4268 LP55.



Fletcher, M, **Deming P**, Thornton K, Arora S. Use of sofosbuvir in chronic hepatitis C virus (HCV) infection in patients with cirrhosis. *49<sup>th</sup> Annual American Society for Health-Systems Pharmacists* Anaheim, CA. December 2014.

Kalishman S, Iandiorio M, **Deming P**, Anderson J, Roper V. Implementing an interprofessional chronic, complex disease rotation using Project ECHO innovation. *University of New Mexico: Exemplars in IPE*. Albuquerque, NM. October 28, 2014.

Kalishman S, Iandiorio M, **Deming P**, Anderson J, Roper V. Implementing an interprofessional chronic, complex disease rotation using Project ECHO innovation. *Annual Western Group on Educational Affairs Conference* Honolulu, HI. March 23-25, 2014.

Dionne, B, **Deming P**, Thornton K, Walraven C, Arora S. Treatment outcomes using protease inhibitors for hepatitis C virus infection in clinical practice. *48<sup>th</sup> Annual American Society for Health-Systems Pharmacists* Orlando, FL. December 2013.

**Deming, P**, Anderson J, Dodd M, Johnson B, Holdsworth M, Mercier RC, Ray G, Thornton K, Arora S. Project ECHO: A novel method for clinical pharmacists in a multidisciplinary telehealth care network for rural and underserved communities. *American College of Clinical Pharmacists Annual Meeting* Albuquerque, NM. October 2013.

**Deming P**, Thornton K, Kalishman S, Murata G, Arora S. Project ECHO (Extension for Community Healthcare Outcomes) Expands Access to Hepatitis C Treatment for Underserved Populations. *American College of Clinical Pharmacists Annual Meeting* Albuquerque, NM. October 2013.

Henrie A, Wittstrom K, **Deming, P**. Evaluation of liver dysfunction as prognostic factor with survival after Yttrium-90 radioembolization used to treat liver malignancies. *American College of Clinical Pharmacists Annual Meeting* Albuquerque, NM. October 2013.

Arora, S, Thornton K, Murata G, **Deming P**, Kalishman S. Project ECHO: Outcomes of hepatitis C treatment by primary care providers. *The 2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention, and Access to Care*. Washington, DC. November 26-28, 2012.

Montoya M, **Deming P**, The efficacy of vitamin D supplementation in patients with chronic hepatitis C virus. *32<sup>nd</sup> Annual Western States Conference for Pharmacy Residents, Fellows, and Preceptors*. Pacific Grove, CA. May 2012.

Borrego ME, Marshik P, Kharat A, Bachyrycz A, Dodd M, Anderson J, Bond R, **Deming P**, Goddard N, Johnson B, Mercier R, Nawarskas J, Ray G, Salazar, K. Attitudes, experience and use regarding complementary and alternative medicines and therapies (CAMT) in people living in New Mexico. *Annual Meeting of the American Pharmacists Association*, New Orleans, LA, March 9-12, 2012

Montoya, Montoya, **Deming P**, The efficacy of vitamin D supplementation in patients with chronic hepatitis C virus. *46<sup>th</sup> Annual American Society for Health-Systems Pharmacists*. New Orleans, LA, December 2011.

North, MS, Thornton K, **Deming P**, Mercier RC. An integrative approach to the treatment of chronic hepatitis C virus (HCV) in coinfecting patients with human immunodeficiency virus (HIV). *31<sup>st</sup> Annual Western States Conference for Pharmacy Residents, Fellows, and Preceptors*. Pacific Grove, CA. May 2011.

Arora, S, Thornton K, Murata G, **Deming P**, Kalishman S, Dion D, Parish B, Dunkelberg J, Kistin M, Pak M, Brown J. Project ECHO expands access to hepatitis c (HCV) treatment in rural areas and prisons. Treatment is as effective as a university HCV clinic. *46<sup>th</sup> Annual Meeting of the European Association for the Study of the Liver*, Berlin, Germany. March 30-April 3, 2011.

North, MS, Thornton K, **Deming P**, Mercier RC. An integrative approach to the treatment of chronic hepatitis C virus (HCV) in coinfecting patients with human immunodeficiency virus (HIV). *45<sup>th</sup> Annual American Society for Health-Systems Pharmacists*. Anaheim, CA. December 2010.

North, M, Werth B, Sliwinski J, **Deming P**, Sakoulas G, Mercier RC. Relationship of microbiological and virulence characteristics to staphyloxanthin (STX) production in methicillin-resistant *Staphylococcus aureus* (MRSA). *American College of Clinical Pharmacy Annual Meeting*. Austin, TX. October 2010.

Walraven CJ, North M, **Deming P**, Mercier R. Disease state, not MIC, predicts vancomycin failures. *50<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy*. Boston, MA. September 2010.

North M, **Deming P**, Hrebickova L, Mercier R. Clinical and microbiological outcomes associated with the pigment production of methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia in hospitalized patients. *30<sup>th</sup> Annual Western States Conference for Pharmacy Residents, Fellows, and Preceptors*. Pacific Grove, CA. May 2010.

North M, **Deming P**, Hrebickova L, Mercier R. Clinical and microbiological outcomes associated with the pigment production of methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia in hospitalized patients. *44<sup>th</sup> Annual American Society for Health-Systems Pharmacists*. Las Vegas, NV. December 2009.

**Deming P**, Werth B, Montoya M, Werth C, Sliwinski J, Young S, Sakoulas G, Mercier RC. Identification of MRSA strains as an independent risk factor in hospitalized patient outcome. *2009 American College of Clinical Pharmacy Annual Meeting*. Anaheim, CA. October 2009.

Arora S, Thornton K, Kalishman S, Murata G, Fassler C, Dion D, **Deming P**, Brown J, Parish, B, Pak W. Project ECHO (Extension for Community Healthcare Outcomes) expands access to hepatitis C (HCV) treatment in rural areas and prisons: care is as effective as a university HCV clinic. *2009 Agency for Healthcare Research and Quality Annual Conference*. Bethesda, MD. September 2009.

Werth C, **Deming P**, Montoya M, Sliwinski J, Young S, Mercier RC. Methicillin-resistant *Staphylococcus aureus* (MRSA): Comparison of methodologies to determine vancomycin (VAN) minimum inhibitory concentration (MIC) and correlation with clinical outcomes. *49<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy*. San Francisco, CA. September 2009.

Boyd N, Young S, **Deming P**, Mercier RC, Werth CM. Assessment of methods for detecting reduced susceptibility to vancomycin for methicillin-resistant *Staphylococcus aureus* bacteremia. *49<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy*. San Francisco, CA. September 2009.

Werth C, **Deming P**, Mercier RC. Methicillin-resistant *Staphylococcus aureus*: Comparison of methodologies to determine vancomycin minimum inhibitory concentration and correlation with clinical outcomes. *29<sup>th</sup> Annual Western States Conference for Pharmacy Residents, Fellows, and Preceptors*. Pacific Grove, CA. May 2009.

Boyd N, Young S, **Deming P**, Mercier RC, Werth CM. Assessment of methods for detecting reduced susceptibility to vancomycin for methicillin-resistant *Staphylococcus aureus* bacteremia. *29<sup>th</sup> Annual Western States Conference for Pharmacy Residents, Fellows, and Preceptors*. Pacific Grove, CA. May 2009.

Werth C, **Deming P**, Mercier RC. Methicillin-resistant *Staphylococcus aureus*: Comparison of methodologies to determine vancomycin minimum inhibitory concentration and correlation with clinical outcomes. *43<sup>rd</sup> Annual Meeting: American Society for Health-Systems Pharmacists*. Orlando, FL. December 2008.

Montierth, K, Hrebickova L, Marinaro J, **Deming P**. Pseudoephedrine effects on MAP in stable ICU patients with arterial catheters. *28<sup>th</sup> Annual Western States Conference for Pharmacy Residents, Fellows, and Preceptors*. Pacific Grove, CA. May 2008

Montierth, K, Hrebickova L, Marinaro J, **Deming P**. Pseudoephedrine effects on MAP in stable ICU patients with arterial catheters. *42<sup>nd</sup> Annual American Society for Health-Systems Pharmacists*. Las Vegas, NV. December 2007.

Hrebickova, L, Pai M, DeCoster T, Young S, **Dziamka P**, Mercier RC. Assessment of bacterial survival and systemic tobramycin concentrations associated with the use of tobramycin-impregnated PMMA beads. *46<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy*. San Francisco, CA. September 2006

**Dziamka P**, Pai M, Walker M, Young S, Mercier RC. MRSA strains as an independent risk factor in hospitalized patient outcome. *26<sup>th</sup> Annual Western States Conference for Pharmacy Residents, Fellows, and Preceptors*. Pacific Grove, CA. May 2006.

**Dziamka P**, Namdar R, Wright H, Pai M, Hrebickova L, Young S, Mercier RC. Identification of MRSA strains as an independent risk factor in hospitalized patient outcome. *25<sup>th</sup> Annual Western States Conference for Pharmacy Residents, Fellows, and Preceptors*. Pacific Grove, CA. May 2005.

**Dziamka P**, Namdar R, Wright H, Pai M, Hrebickova L, Young S, Mercier RC. Identification of MRSA strains as an independent risk factor in hospitalized patient outcome. *40<sup>th</sup> Annual American Society for Health-Systems Pharmacists*. Las Vegas, NV. December 2005.

## PUBLICATIONS

---

Mera J, Joshi K, Thornton K, Box T, Scott J, Sedillo M, **Deming P**, David C, Essex W, Manch R, Kohli A. Retrospective study demonstrating high rates of sustained virologic response after treatment with direct-acting antivirals among American Indian/Alaskan Natives. *Open Forum Infect Dis*. 2019;6: ofz128. doi: 10.1093/ofid/ofz128

**Deming P**, Spooner L. Specialty considerations in management of hepatitis C. *Pharmacy Today*. 2017 Nov;23:55-64.

Martin MT, **Deming P**. Closing the Gap: The challenges of treating hepatitis C virus genotype 3 infection. *Pharmacotherapy*. 2017;37:735-747.

K Thornton, **Deming P**, Manch RA, Moore A, Kohli A, Gish R, Sussman NL, Khaderi S, Scott J, Mera J, Box T, Qualls C, Sedillo M, Arora S. Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment. *Hepatol Int*. 2016 Jul;10:624-631.

**Deming P**, Martin MT, Chan J, Dilworth TJ, El-Lababidi R, Love BL, Mohammadra R, Nguyen A, Spooner LM, Wortman SB. Therapeutic advances in HCV genotype 1 infection: Insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy*. 2016 Feb; 36:203-17.

Marshik PL, Kharat AA, Jakeman B, Borrego ME, Dodd MA, Bachyrycz A, Anderson JR, Bond R, **Deming P**, Mercier RC, Nawarskas JJ, Ray G, Salazar K. Complementary and alternative medicine and therapy use in a diverse New Mexican population. *J Altern Complement Med*. 2016 Jan;22:45-51.

Henrie AM, Wittstrom K, Delu A, **Deming P**. Evaluation of liver biomarkers as prognostic factors for outcomes to yttrium-90 radioembolization of primary and secondary liver malignancies. *Cancer Biother Radiopharm* 2015 Sept;30(7):305-9.

Mohammad RA, Bulloch MN, Chan J, **Deming P**, Love B, Smith L, Dong BJ. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection. Joint Opinion Paper of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. *Pharmacother* 2014;34:1341-1354.

Quinn D, Kuchler E, **Deming P**, Arora S. Catatonia associated with pegylated interferon- $\alpha$  2b and ribavirin for hepatitis C. *Psychosomatics*. 2012 Jul-Aug;53:400-1.

**Deming P**, Arora S. Taribavirin in the treatment of hepatitis C. *Expert Opin Investig Drugs*. 2011 Oct;20(10):1435-43.

Walraven CJ, North MS, Marr-Lyon L, **Deming P**, Sakoulas G, Mercier RC. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant bacteremia. *J Antimicrob Chemother* 2011 Oct;66(10):2386-92.

Arora S, Thornton K, Murata G, **Deming P**, Kalishman S, Dion D, Parish B, Burke T, Pak W, Dunkelberg J, Kistin M, Brown J, Jenkusky S, Komaromy M, Qualls C. Outcomes of treatment for hepatitis C virus infection by primary care providers. *N Engl J Med* 2011 Jun 9;364(23):2199-207.

Arora S, Kalishman S, Dion D, Som D, Thornton K, Bankhurst A, Boyle J, Harkins M, Moseley K, Murata G, Komaramy M, Katzman J, Colleran K, **Deming P**, Yutzy S. Partnering urban academic medical centers and rural primary care clinicians to provide complex chronic disease care. *Health Aff (Millwood)*. 2011 Jun;30(6):1176-84.

**Deming P**, McNicholl I. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists. *Pharmacother* 2011;31:357-68.

Arora S, Kalishman S, Thornton K, Dion D, Murata G, **Deming P**, Parish B, Brown J, Komaromy M, Colleran K, Bankhurst A, Katzman J, Harkins M, Curet L, Cosgrove E, Pak W. Expanding access to hepatitis C virus treatment—Extension for Community Healthcare Outcomes (ECHO) Project: disruptive innovation in specialty care. *Hepatology* 2010;52:1124-33.

#### **BOOK CHAPTERS (Published)**

---

**Deming P**. Viral Hepatitis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Ed. *Pharmacotherapy: A Pathophysiologic Approach 11<sup>th</sup> Edition*, Chicago, McGraw-Hill 2019.

**Deming P**. Hepatitis C Virus Infection. In American College of Clinical Pharmacy. *PSAP Pharmacotherapy Self-Assessment Program Book 1: Infectious Diseases*. Kansas City, MO: ACCP, 2018.

**Deming P**. Viral Hepatitis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Ed. *Pharmacotherapy: A Pathophysiologic Approach 10<sup>th</sup> Edition*, Chicago, McGraw-Hill 2017.

**Deming P**, Mercier RC. Intraabdominal Infections. In Schwinghammer T and Koehler J, Ed. *Pharmacotherapy Casebook: A Patient-Focused Approach 10<sup>th</sup> Edition*, Chicago, McGraw-Hill 2017.

Mercier RC, **Deming P**. Diabetic Foot Infections. In Schwinghammer T and Koehler J, Ed. *Pharmacotherapy Casebook: A Patient-Focused Approach 10<sup>th</sup> Edition*, Chicago, McGraw-Hill 2017.

**Deming P**. Viral Hepatitis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Ed. *Pharmacotherapy: A Pathophysiologic Approach 9<sup>th</sup> Edition*, Chicago, McGraw-Hill 2014.

**Deming P**, Mercier RC. Intraabdominal Infections. In Schwinghammer T and Koehler J, Ed. *Pharmacotherapy Casebook: A Patient-Focused Approach 9<sup>th</sup> Edition*, Chicago, McGraw-Hill 2014.

Mercier RC, **Deming P**. Diabetic Foot Infections. In Schwinghammer T and Koehler J, Ed. *Pharmacotherapy Casebook: A Patient-Focused Approach 9<sup>th</sup> Edition*, Chicago, McGraw-Hill 2014.

**Deming P**, Mercier RC. Intraabdominal Infections. In Schwinghammer T and Koehler J, Ed. *Pharmacotherapy Casebook: A Patient-Focused Approach 8<sup>th</sup> Edition*, Chicago, McGraw-Hill 2011.

Mercier RC, **Deming P.** Diabetic Foot Infections. In Schwinghammer T and Koehler J, Ed. *Pharmacotherapy Casebook: A Patient-Focused Approach 8<sup>th</sup> Edition*, Chicago, McGraw-Hill 2011.

**Deming P.** Viral hepatitis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Ed. *Pharmacotherapy: A Pathophysiologic Approach 8<sup>th</sup> Edition*, Chicago, McGraw-Hill 2011.

**Deming P.** Viral hepatitis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Ed. *Pharmacotherapy: A Pathophysiologic Approach 7<sup>th</sup> Edition*, Chicago, McGraw-Hill 2007.

## **REVIEWER**

---

Open Forum Infectious Diseases 2019

BMC Health Services Research 2019

American Journal of Health Systems Pharmacy 2019

Journal of Pharmacy Technology 2018

Annals of Pharmacotherapy 2017, 2019

Post-Graduate Healthcare Education 2017

Pharmacist's Letter 2016

American College of Clinical Pharmacy Pharmacotherapy Self-Assessment Program (PSAP) Reviewer: Hepatitis C 2015

Pharmacotherapy 2014, 2015, 2016, 2019

HIV/AIDS - Research and Palliative Care 2013

American College of Clinical Pharmacy Pharmacotherapy Self-Assessment Program VII-(PSAP-VII) Reviewer: Complications of Chronic Liver Disease 2012

Mayo Clinical Proceedings 2011

Journal of Medical Virology 2011

AIDS Research and Treatment 2011

American College of Clinical Pharmacy Pharmacotherapy Self-Assessment Program VI-(PSAP-VI) Reviewer: Viral Hepatitis 2008

## **INVITED SPEAKER**

---

Hepatitis C Clinical Training for Indian/Tribal/ Urban Facilities (featured faculty and speaker): HCV Screening, Management, and Treatment Guidelines. *Northwest Portland Area Indian Health Board and Northern Tier Initiative for Hepatitis C Elimination Project*. Rapid City, SD. Oct. 23-24, 2019.

LEGA-C Medical Affairs Advisory Meeting: The ECHO Model. *Gilead Sciences*. Foster City, CA. Oct 10-11, 2019.

Hepatitis C Gathering for Community and Clinicians: Hepatitis 101; HCV Update. *The Navajo Nation*. Window Rock, AZ. May 2-3, 2019.

Hepatitis C Clinical Training for Indian/Tribal/ Urban Facilities (featured faculty and speaker): HCV Screening, Management, and Treatment Guidelines. *Northwest Portland Area Indian Health Board and Northern Tier Initiative for Hepatitis C Elimination Project*. Phoenix, Az. April 4-5, 2019.

Direct Acting Antivirals for Hepatitis C Virus Infection. *Indian Health Services National Pharmacy & Therapeutics Committee Fall Meeting*. Oklahoma City, OK. Nov. 1, 2018.

The Path to Health: Elimination of Infectious Threats in the Four Corners Area. How to Manage Co-Infection with Hepatitis C and HIV. *Four Corners Public Health Annual Meeting*. Santa Fe, NM. Nov. 7, 2018.

Hepatitis C Clinical Training for Indian/Tribal/ Urban Facilities (featured faculty and speaker): HCV Screening, Management, and Treatment Guidelines. *Northwest Portland Area Indian Health Board and Northern Tier Initiative for Hepatitis C Elimination Project*. Billings, MT. Oct. 5-6, 2018.

Hepatitis C Virus Treatment. Accelerating HCV Response in Indian Country. Albuquerque, NM. May 3-4, 2018

Interactive Session: HCV Patient Cases. *2018 Annual New Mexico HIV and HCV Update*. Albuquerque, NM. April 26, 2018.

Your Annual Hepatitis C Update. *American Pharmacists Association Annual Meeting*. Nashville, TN. March 19, 2019.

Hepatitis C Clinical Training for Indian/Tribal/ Urban Facilities (featured faculty and speaker): HCV Screening, Management, and Treatment Guidelines. *Northwest Portland Area Indian Health Board and Northern Tier Initiative for Hepatitis C Elimination Project*. Rapid City, SD. Jan. 30-31, 2018.

ASHP Educational Session: Ready or Not, Here it Comes: Updates for Management of Hepatitis C Virus Across Practice Settings. *American Society of Health-Systems Pharmacists Annual Meeting* Orlando, FL. Dec. 6, 2017.

Project ECHO (Extension for Community Healthcare Outcomes): A Revolution in Medical Education and Care Delivery. *Farmacia Hospitalaria Reunion Otono en HCV*. Madrid, Spain. November 24-25, 2017.

HCV-HIV Coinfection Patient Case Roundtable. *2017 Annual New Mexico HIV Update*. Albuquerque, NM May 4, 2017.

Specialty Considerations in the Management of Hepatitis C. *American Pharmacists Association Annual Meeting* San Francisco, California. March 24-27, 2017.

Pharmaceutical Industry PRN and Health Outcomes PRN Focus Session- Cost-Efficacy vs Clinical Efficacy and the Impact on Clinical Choice. Session: Cost-effectiveness Data and Its Impact on Appropriateness of Treatment and Access to Care for HCV. *2016 American College of Clinical Pharmacy Annual Meeting*, Hollywood, FL. Oct. 25, 2016.

2016 From Theory to Practice: Clinical Reasoning Series in Ambulatory Care Pharmacy. Hepatitis C: The Newest Strategies for Management and Treatment. Sessions: Retreatment and Resistance; Challenges with HCV Treatment. *2016 American College of Clinical Pharmacy Annual Meeting*, Hollywood, FL. Oct. 22, 2016.

Sofosbuvir/Velpatasvir. Clinical Advisory Committee Ventegra Formulary Review. September 12, 2016.

HCV Treatment in the Era of Direct Acting Antivirals. *Western Medicaid Pharmacy Administrators Association Meeting*. Santa Fe, NM September 8, 2016.

An Update on Hepatitis C. *Making A Difference in ID: 2016 Annual Meeting*. Orlando, Florida. May 6, 2016.

HCV-HIV Coinfection Patient Case Roundtable. *2016 Annual New Mexico HIV Update*. Albuquerque, NM March 24, 2016.

Drug Dosing in Cirrhosis and HCV Therapies from an In-Patient Perspective: Guide for Pharmacists (Part of UNM COP Preceptor Development Series). Presbyterian Hospital, Albuquerque, NM. January 7, 2016.

Hepatitis C Update Workshop. *2015 Annual New Mexico HIV Update*. Albuquerque, NM April 30- May 1, 2015.

HCV-HIV Coinfection Patient Case Roundtable. *2015 Annual New Mexico HIV Update*. Albuquerque, NM April 30- May 1, 2015.

The HCV Treatment Revolution: Current and Emerging Therapies for Chronic HCV. *New Mexico Pharmacists Association Mid-Winter Meeting*. Albuquerque, NM January 24-25, 2015.

Sofosbuvir/Ledipasvir for HCV: Basics and Emerging Clinical Data. *Division of Infectious Diseases Teaching Rounds. University of New Mexico Health Sciences Center*. December 18, 2014.

HCV Symposium: Focus on Special Populations- Transplantation, Cirrhosis, and Renal Insufficiency. *2014 American College of Clinical Pharmacy Annual Meeting*. Austin, TX October 14, 2014.

Interferon-Free Hepatitis C Regimens: New Therapies, New Recommendations- A Guide for Pharmacists *New Mexico Health-Systems Pharmacists Annual Balloon Fiesta Symposium*. Albuquerque, NM October 6, 2014.

The HCV Treatment Revolution: Emerging Therapies for Chronic HCV. *New York State Chapter of the American College of Clinical Pharmacists Annual Meeting*. Rochester, NY September 18, 2014.

HCV: New Therapies and Management Issues. *Presbyterian Healthcare Services Grand Rounds*. Albuquerque, NM September 9, 2014.

HCV: New Therapies and Management Issues. *Northwest Region Public Health Department Clinical Meeting*. Albuquerque, NM July 15, 2014.

HCV-HIV Coinfection Patient Case Roundtable. *2014 Annual New Mexico HIV Conference*. Albuquerque, NM April 24-25, 2014.

The Project ECHO Experience (collaborative presentation with Dr. Amy Nguyen in “Hepatitis C: Patient Screening, New Treatments, and Roles for Pharmacists in Therapy Delivery”) *Indian Health Services 2014 Pharmacists QUAD Meeting*. Phoenix, Arizona April 4-5, 2014.

Interferon Free Hepatitis C Regimens: Coming Soon to Your Pharmacy- *American Pharmacists Association Annual Meeting* Orlando, Florida March 28-31, 2014.

New Therapies and Challenges in the Hepatitis C Epidemic: Linkage to Care with Project ECHO. *Medicaid Evidence Based Decisions/ Drug Effectiveness Review Project Fall Conference*. Portland, Oregon October 23-24, 2013.

The Role of Infectious Disease Specialists in Hepatitis C. *Arizona Regional Infectious Diseases Society Meeting* Sedona, Arizona March 1-3, 2013.

Update on Treatment of Hepatitis C *New Mexico Rio Grande Chapter of the Society of Gastroenterology Nurses and Associates: 19<sup>th</sup> Annual Spring Gastroenterology Seminar*, Albuquerque, NM April 14, 2012.

Chronic Hepatitis C Update. *New Mexico Health Systems Pharmacists Annual Balloon Fiesta Symposium*. Albuquerque, NM October 1-4, 2011.

Viral Hepatitis C. *New Mexico Pharmacists Association Annual Meeting*. Albuquerque, NM June 25-26, 2011. (Joint session with A. Bachyryz, PharmD and J. Conklin, PharmD)

Viral Hepatitis C. *Indian Health Services: National HIV Screening Conference*, Phoenix, AZ June 1-2, 2011.

Prescriptive Drug Abuse. Training Class: University of Oklahoma/ Alcohol Tobacco and Other Drug Abuse Prevention Task Force. June 28, 2010

Treatment of Hepatitis C *New Mexico Pharmacists Association 80<sup>th</sup> Annual Convention*, Albuquerque, NM June 27, 2009

Treatment of Hepatitis C *New Mexico Rio Grande Chapter of the Society of Gastroenterology Nurses and Associates: 16<sup>th</sup> Annual Spring Gastroenterology Seminar*, Albuquerque, NM April 4, 2009

### **PROJECT ECHO DIDACTIC LECTURES For Clinicians (CME/CEU/CPE)**

---

“Changes in Prescribing Eplclusa” December 19, 2019 Corrections Clinic

“Changes in Liver Disease After HCV Cure” October 17, 2019 Corrections Clinic

“Common HCV Drug-Drug Interactions” September 12, 2019 Corrections Clinic

“Use of Ribavirin for Genotype 3: EASL Update” September 11, 2019 HCV Community Clinic

“FDA Warning: Serious Liver Injury with HCV Protease Inhibitors” September 4, 2019 HCV Community Clinic; Indian Country HCV Clinic; September 5, 2019 Corrections; September 10, 2019 HIV HCV Clinic

“Calculating a Child Pugh Score” August 29, 2019 Corrections Clinic

“Oxcarbazepine Interaction with HCV DAAs” August 15, 2019 Corrections Clinic

“What’s the Big Deal with HAV Infections?” July 25, 2019 Corrections Clinic; August 13, 2019 HIV HCV Clinic

“HCV Screening Guidelines” July 9 2019 HIV HCV Coinfection Clinic

“Long Term Follow Up after HCV Treatment” June 5, 2019 Indian Country HCV Clinic; June 6, 2019 Corrections Clinic; June 11, 2019 HIV HCV Clinic; October 3, 2019 Corrections Clinic

“Mechanism of Action of HCV DAAs” May 30, 2019 Corrections Clinic

“Updates in HCV: Screening, Management, and Treatment of Patients with HCV” May 14, 2019 HIV HCV Clinic

“HCV and Diabetes” May 2, 2019 Corrections Clinic

“Cirrhosis: Compensated vs. Decompensated” April 18, 2019 Corrections Clinic

“Medications to Avoid in Liver Disease” March 7, 2019 Corrections Clinic; November 6, 2019 Indian Country HCV Clinic

“Resistance Testing, Part 2” January 31, 2019 Corrections Clinic

“Resistance Testing, Part 1” January 24, 2019 Corrections Clinic

“Acid Suppressive Therapy Interactions with HCV Medications” January 17, 2019 Corrections Clinic



“Gilead Generic HCV Medications” January 9, 2019 HCV Community Clinic; January 16, 2019 Indian Country HCV Clinic; February 12, 2019 HIV HCV Coinfection Clinic

“Update from AASLD 2018: Reinfection of HCV in People on Opioid Substitution” December 18, 2018 HIV HCV Clinic; December 19, 2018 Community Clinic, Indian Country Clinic; December 20, 2018 Corrections Clinic

“Hepatitis Debrief” November 29, 2018 Corrections Clinic

“HCV Resistance in Genotype 1a” November 1, 2018 Corrections Clinic

“Role of Ribavirin in DAA Therapy” October 17, 2018 Community Clinic; October 18, 2018 Corrections Clinic

“Use of Zepatier” October 11, 2018 Corrections Clinic

“Retreatment of Harvoni Failures” September 7, 2018 Georgia Clinic (International)

“HeplisavB Vaccine” August 15, 2018 Community Clinic; September 19, 2018 Indian Country Clinic

“Effects of Cannabis on Liver Disease” August 9, 2018 Corrections Clinic; September 11, 2018 HIV HCV Clinic

“Compensated vs Decompensated Cirrhosis: Choosing HCV Therapy” July 26, 2018 Corrections Clinic

“AASLD Guidelines” June 20, 2018 Indian Country Clinic, Community Clinic; June 26, 2018 HIV HCV Clinic; August 16, 2018 Corrections Clinic

“Relapse and Reinfection” June 6 2018 Indian Country Clinic, Community Clinic; June 14, 2018 Corrections Clinic

“Safety of DAA therapy in Pregnancy and Breastfeeding” May 2, 2018 Community HCV Clinic; May 8 2018 HIV HCV Clinic

“HBV Reactivation” March 7, 2018 Community Clinic; March 13, 2018 HIV HCV Clinic; March 29, 2018 Corrections Clinic

“Vosevi- Clinician’s Guide to Use” March 1, 2018 Corrections Clinic

“SVR and Mortality” February 8, 2018 Corrections Clinic

“Long-term Follow up After HCV Treatment” January 25, 2018 Corrections Clinic; February 7, 2018 Indian Country Clinic; September 19, 2018 Community Clinic

“Impact of SVR on Quality of Life” January 18, 2018 Corrections Clinic; February 13, 2018 HIV HCV Clinic

“Impact of SVR on Cirrhosis and Extrahepatic Manifestations of HCV” December 14, 2017 Corrections Clinic; November 15, 2017 Community Clinic

“Mavyret- Clinician’s Guide to Use” November 16, 2017 Corrections Clinic; September 28, 2017 Corrections Clinic; August 30, 2017 Community Clinic

“HCV Resistance Primer” November 1, 2017 Community Clinic, November 1, 2017 IHS HCV Clinic; November 9, 2017 Corrections Clinic

“AASLD Update on Management of Genotype 1” October 4, 2017 Community Clinic; October 12, 2017 Corrections Clinic

“Updated HCV Treatment Guidelines” October 18, 2017 IHS HCV Community Clinic; September 27, 2017 Community Clinic

“Retreatment in Patients who have Failed NS5A Inhibitor Containing Therapy” September 20, 2017 IHS HCV Clinic; September 20, 2017 Community Clinic

“Sofosbuvir/Velpatasvir/Voxilaprevir: Guide for Clinicians” August 17, 2017 Corrections Clinic; August 16, 2017 Community Clinic

“HCV Reinfection Rates Among Persons Who Inject Drugs” June 14, 2017 Community Clinic; June 15, 2017 Corrections Clinic

“HCV Treatment in Persons Receiving Opiate Substitution Therapy” June 6, 2017 Community Clinic; June 7, 2017 Corrections Clinic

“HCV Treatment in Persons Who Inject Drugs” June 1, 2017 Corrections Clinic

“Update from CROI: SVR Rates in FQHCs” April 5, 2017 Community Clinic

“Specific Medication Issues in Cirrhosis” March 29, 2017 Community Clinic

“Medications to Avoid in Liver Disease” March 22, 2017 Community Clinic; March 16, 2017 Corrections Clinic

“HCV Treatment and Care Management” February 13, 2017 Corrections Clinic

“Genotype 3 Infection: A Risk Factor for Worse Outcome?” February 1, 2017 IHS HCV Clinic; January 19, 2017 Corrections Clinic; January 18, 2017 Community HCV Clinic

“Assessment of Liver Disease: Identifying Cirrhosis using Laboratory Markers” January 12, 2017 Corrections Clinic

“Ribavirin and Pregnancy” January 4, 2017 Community Clinic

“FAQ: HCV Resistance.” December 14, 2016 Community Clinic

“Counseling Patients with HCV.” December 1, 2016 Corrections Clinic

“Changes In HCV Therapy: What is the Role of Ledipasvir/Sofosbuvir for 8 Weeks?” November 16, 2016 Community Clinic

“HCV Direct Acting Antivirals Update.” November 1, 2016 Community Clinic

“Retreatment of DAA Failures.” October 12, 2016 Community Clinic; October 20, 2016 Corrections Clinic

“Zepatier Overview.” October 17, 2016 Country of Georgia HCV Elimination Project (International)

“HCV Resistance Recap of 2016 Challenges and Emerging Issues.” September 28, 2016 and October 5, 2016 Community Clinic; October 6 and October 13, 2016 Corrections Clinic; November 1, 2016 HIV NM Clinic

“Pregnancy Risks with Ribavirin.” September 14, 2016 Community Clinic

“Using Ribavirin.” September 8, 2016 Corrections Clinic

“Eplclusa Drug-Drug Interactions.” July 20, 2016 Community Clinic; July 21, 2016 Corrections Clinic

“Eplclusa Prescribing Overview.” July 6, 2016 Community Clinic; July 7, 2016 Corrections Clinic

“Eplclusa Overview.” July 6, 2016 IHS HCV Clinic; July 12, 2016 HIV NM Clinic

“Sofosbuvir-based Treatments for Pediatric Patients.” June 27, 2016 Country of Georgia HCV Elimination Project (International)

“Clinical Guidelines Update.” June 8, 2016 Community Clinic

“HCV Resistance.” May 19, 2016 Corrections Clinic

“NM Drug Donation Program” May 18, 2016 IHS HCV Clinic; May 18, 2016 Community HCV Clinic; May 19 IHS HCV Clinic; June 7, 2016 HIV NM Clinic

“Pharmacotherapy Considerations in Patients with Cirrhosis of the Liver.” April 13 and 20, 2016 Community HCV Clinic; April 28, 2016 Corrections Clinic

“Adverse Effects with Ribavirin.” March 17, 2016 Corrections HCV Clinic; September 7, 2016 Community HCV

“Drug Interactions with Ledipasvir/Sofosbuvir.” March 10, 2016 Corrections HCV Clinic.

“Drug Drug Interactions with Harvoni and Adverse Effects of Ribavirin.” March 7, 2016 Country of Georgia HCV Elimination Project (International)

“Management of HCV.” March 7, 2016 Complex Care Clinic

“Zepatier, part 2.” Feb. 24, 2016 Community HCV Clinic.

“Zepatier.” Feb. 17, 2016 Community HCV Clinic; March 1, 2016 HIV NM Clinic; March 2 IHS HCV Clinic

“Winter 2016 Therapy Updates.” Feb. 10, 2016 Community HCV Clinic; Feb. 11, 2016 Corrections HCV Clinic.

“AASLD Update: HCV Treatment Options Expected in the Near Future.” Feb. 3, 2016 Community HCV Clinic

“AASLD Update: Daclatasvir and Sofosbuvir for GT3.” Jan. 27, 2016 Community HCV Clinic; Jan. 28, 2016 Corrections HCV Clinic; Feb. 3, 2016 IHS HCV Clinic

“AASLD Update: Currently Available HCV Therapies: Real-World Experience- HCC, SVR, and Predictors of Failure.” Jan. 20, 2016 Community HCV Clinic; Jan. 21, 2016 Corrections HCV Clinic

“Summary of HCV Resistance: Who, What, and Why” Jan. 6, 2016 Community HCV Clinic

“HCV Resistance to NS5B Inhibitors” December 16, 2015 Community HCV Clinic

“Overview of HCV Resistance and Testing” December 15, 2015 HIV-HCV Coinfection Clinic

“HCV Resistance Testing” December 9, 2015 Community HCV Clinic

“Update on Harvoni Prescribing Info” November 18, 2015 Community HCV Clinic, November 19, 2015 Corrections HCV Clinic

“HCV Resistance to NS3 Protease Inhibitors” November 11, 2015 Community HCV Clinic

“Overview of Drug-Drug Interactions” November 5, 2015 Corrections HCV Clinic

“Safety Update for Viekira Pak and Technivie” November 4, 2015 Community HCV Clinic

“Introduction to HCV Resistance” September 16, 2015 Community HCV Clinic

“Updated Treatment Decision Trees” September 16, 2015 Community HCV Clinic

“Treatments for HCV Genotype 3” August 12, 2015 Community HCV Clinic

“Daclatasvir” July 29, 2015 Community HCV Clinic, August 5, 2015 IHS HCV Clinic

“RUBY-1 Study- Update from EASL” July 15, 2015 Community HCV Clinic

“TURQUOISE-III: Safety and Efficacy of 12-Week Ribavirin-Free Treatment for Patients with HCV Genotype 1b and Cirrhosis” July 1, 2015 Community HCV Clinic, IHS HCV Clinic

“Cirrhosis of the Liver: Implications for Medication Use” May 6, 2015 Community HCV Clinic

“Assessing Advanced Fibrosis and Cirrhosis of the Liver” April 1, 2015 Community HCV Clinic, IHS HCV Clinic

“Gilead Safety Letter on Sofosbuvir-Containing Regimens” March 25, 2015 Community HCV Clinic

“Retreatment of Sofosbuvir Failures” February 25, 2015 Community HCV Clinic, March 3, 2015 IHS HCV Clinic

“VieKira for Special Populations: Renal, Hepatic, Transplant, and HIV-Coinfection” February 11, 2015 Community HCV Clinic

“Updated Treatment Decision Trees and Treatment Flowsheets” January 28, 2015 Community HCV Clinic, February 4, 2015 IHS HCV Clinic

“VieKira Drug-Drug Interactions” January 21, 2015 Community HCV Clinic

“VieKira Pak” January 7, 2015 Community HCV Clinic, IHS HCV Clinic

“Sofosbuvir/Ledipasvir plus Ribavirin in Patients with Decompensated Cirrhosis” December 17, 2014 Community HCV Clinic

“Sofosbuvir/Ledipasvir plus Ribavirin in Previously Treated Patients with Cirrhosis” December 3, 2014 Community HCV Clinic

“Cirrhosis” December 1, 2014 Complex Care Clinic Clinician Education

“Negative Predictive Factors with Sofosbuvir” April 16, 2014 Community HCV Clinic, June 4, 2014 IHS HCV Clinic

“Extrahepatic Manifestations of HCV” September 2013 HIV-HCV Coinfection Clinic

“Update on Telaprevir: Black Box Warning” February 2013, Community HCV Clinic

“Accidental Acetaminophen Toxicity” November 26, 2012: Complex Care Clinic

“Rheumatological Manifestations of Hepatitis C Infections” September 26, 2012: Community HCV Clinic

“The Natural History of Hepatitis C Infections” February 15, 2012: Community HCV Clinic

“HCV Treatment Induced Anemia and Association with Outcomes: 2011 Update” November 16, 2011 Community HCV Clinic; November 21, 2011 Corrections HCV Clinic

“Drug Interactions with Boceprevir and Telaprevir” August 2, 2011 Community HCV Clinic

“Adverse Events with Telaprevir and Boceprevir” June 22, 2011 Community HCV Clinic

“HIV-HCV Coinfection” October 6, 2010 Community HCV Clinic

“Vitamin D” March 1, 2010 Project ECHO Corrections HCV Clinic; March 3, 2010 Community HCV Clinic

“Exercise for Weight Loss” December 7, 2009: Corrections HCV Clinic; December 9, 2009: Community HCV Clinic

“Accidental Acetaminophen Toxicity” November 16, 2009: Corrections HCV Clinic; November 18, 2009: Community HCV Clinic; January 21, 2010: Pain Clinic

“Pegasys vs. PegIntron” August 12, 2009 (Part I), August 19, 2009 (Part II): Community HCV Clinic

“Miracle Mineral Solution (MMS)” July 15, 2009: Community HCV Clinic

“Immune Dysfunction in Liver Disease” March 30, 2009: Corrections HCV Clinic; April 1, 2009 Community HCV Clinic

“Rheumatological Manifestations of Hepatitis C Infections” February 2, 2009: Corrections HCV Clinic; February 4, 2009: Community HCV Clinic.

“Parenteral Iron Supplementation” June 11, 2008: Community HCV Clinic

#### **GRAND ROUNDS/ ECHO OUTREACH FOR HEPATITIS C MANAGEMENT**

---

Hepatitis C Training: New Mexico Corrections Department June 22, 2018

Hepatitis C Training: New Mexico Corrections Department March 23, 2018

Indian Health Services/ Acoma-Canoncito-Laguna Hospital (Acoma, New Mexico) September 22, 2016.

Indian Health Services/ Mescalero Indian Hospital (Mescalero, New Mexico) April 11, 2016.

Indian Health Services/ Taos-Picuris Indian Health Center (Taos, New Mexico) January 28, 2016

Indian Health Services/ Standing Rock Sioux Tribe (Fort Yates, North Dakota) December 10, 2015

Indian Health Services/ Cheyenne River Sioux Tribe (Eagle Butte, South Dakota) December 9, 2015

Indian Health Services/ Sioux San Hospital (Rapid City, South Dakota) December 8, 2015

Indian Health Services/ Phoenix Indian Medical Center (Phoenix, Arizona) April 4, 2014

Indian Health Services/Navajo Service Area/Four Corners Regional Health Center (Red Mesa, Arizona), January 23, 2013

Las Clinicas Del Norte (El Rito, New Mexico), April 17, 2012

#### **PROJECT ECHO HCV CLINICIAN TRAINING (CME/CEU/CPE)**

---

Monthly, on-site training for new HCV clinicians- discussion of Project ECHO HCV treatment guidelines and clinic patient discussion  
Aug 2011- present

#### **PUBLIC HEALTH EFFORTS**

---

Interview for KOB channel 4 on HCV and Baby Boomer Screening; May 3, 2018

Faculty Advisor: KOB-TV Health Fair: Hepatitis C Awareness

Faculty Advisor: Hepatitis C Video Awareness Competition: Collaborative effort of the UNM College of Pharmacy APhA Chapter, Project ECHO, Hepatitis C Alliance, and the NM Department of Health

Faculty Advisor: "C Day" UNM College of Pharmacy Hepatitis C Awareness Campaign Across NM: Collaborative effort of UNM College of Pharmacy APhA Chapter, Project ECHO, and the Hepatitis C Alliance

### **OTHER CREATIVE EFFORTS**

---

Treatment Adherence and Education: HIV-HCV Project. Hepatitis C Medicaid Affinity Group (webinar); May 30, 2018

Hepatitis C Module #4: Treatment of HCV in Special Populations, HCV Resistance, and the Future of HCV Therapy. On-line CPE Module for Center for Specialty Pharmacy Education (webinar); January 31, 2017

Arora, S, **Deming P**, Ruge C, Sava S. "Overcoming practice-based barriers: strategies for building a more successful HCV care team" in Medscape Education Infectious Diseases: Clinical Course in HCV 2012. Role: panelist for video media roundtable discussion in CME/CE course; September 25, 2012

### **PROFESSIONAL MEMBERSHIPS**

---

National Viral Hepatitis Roundtable- Pharmacy Workgroup	2016- Present
New Mexico Society of Health Systems Pharmacists	2012-2014
American Association for the Study of Liver Disease	2008- Present
American Society for Microbiology	2004- 2010
Society of Infectious Disease Pharmacists	2004- Present
American College of Clinical Pharmacy	2004- Present
American Pharmaceutical Association	2000- 2005
American Society of Health-System Pharmacists	2000- 2006

### **COMMITTEE MEMBERSHIPS**

---

University of New Mexico COP Curriculum Committee	2009- Present
Chair- Subcommittee: APPE	2015-2016
Co-Chair: Active Learning Task Force	2016-2017
University of New Mexico COP/ UNM Hospital Residency Committee	2007- Present
HCV ECHO Consortium	2012- Present
University of New Mexico COP Dean's P&T Advisory Committee	2015- Present
University of New Mexico COP Research and Scholarship Committee	2014-2015
University of New Mexico School of Medicine Interdisciplinary Home Visit Program	2010- 2014

New Mexico Society of Health Systems Pharmacists Education Committee	2012-2013
Society of Infectious Disease Pharmacists Newsletter Committee	2008- 2010
University of New Mexico COP Pharmacy Reimbursement Committee	2007- 2009

**LICENSES**


---

New Mexico Board of Pharmacy Pharmacist Clinician PC127	March 2006- Present
New Mexico Board of Pharmacy Licensed Pharmacist RP6652	August 2005-Present

**AWARDS**

---

New Mexico Society of Health Systems Pharmacists Dorothy Dillon Memorial Lecture Award Recipient	2018
University of New Mexico College of Pharmacy Faculty Preceptor of the Year Award	2017
University of New Mexico College of Pharmacy P3 Students' Faculty Appreciation Award	2016
Society of Infectious Disease Pharmacists: Gita Patel Best Practices Recognition Award	2014

 Signed